Dr. Garret FitzGerald is the McNeil Professor in Translational Medicine and Therapeutics at the University of Pennsylvania in Philadelphia, where he directs the Institute for Translational Medicine and Therapeutics. Previously he chaired the Department of Systems Pharmacology and Translational Therapeutics for 22 years. Dr. FitzGerald's research has been characterized by an integrative approach to elucidating the mechanisms of drug action, drawing on work in cells, model organisms and humans. His work contributed fundamentally to the development of low-dose aspirin for cardioprotection. FitzGerald's group was the first to predict and then mechanistically explain the cardiovascular hazard from NSAIDs. He has also discovered many products of lipid peroxidation and established their utility as indices of oxidant stress in vivo. His laboratory was the first to discover a molecular clock in the cardiovascular system and has studied the importance of peripheral clocks in the regulation of cardiovascular and metabolic function. Besides membership of the Lyncei he is an Honorary Member of the Royal Irish Academy, and a Member of the US academy of Arts and Sciences, the National Academy of Medicine and the Leopoldina. He is a Fellow of the Royal Society.

Lipid Mediators:

- Wang M, Zukas AM, Hui Y, Ricciotti E, Puré E, FitzGerald GA. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. PNAS  26;103(39);14507-12, 2006.

Molecular Clocks:


• Liang X., Bushman R and FitzGerald G.A. Rhythmicity of the intestinal microbiota is regulated by gender and the host circadian clock. PNAS 112(33):10479-84. 2015. PMCID: PMC4547234


